PDGFRA and gastrointestinal stromal tumor: We are tempted to speculate that in a small subset of patients with GIST with KIT mutations (10 %) and an important subset of WT genotype and PDGFRA mutations (21 %) our proposed immunophenotype bypass KIT signaling.